Dr John Buscombe, Clinical Lead and Consultant in the Department of Nuclear Medicine, Cambridge
University Hospital received the Toshiba Mayneord Award after he delivered a lecture on “Exploring the nature of altheroma in-vivo using PET” at UKRC in Manchester. Dr Buscombe said on receiving this award, “It is a great honour to receive the BIR Toshiba Mayneord award. It was a privilege to deliver the lecture and very exciting to be involved in this ground-breaking area of imaging science.”
Dr Buscombe was presented with a commemorative trophy, a bottle of champagne and a cheque for £1000 by Dr David Wilson, President Elect of the BIR, and Mark Hitchman, Managing Director, Toshiba.
Toshiba have chosen to sponsor this BIR award that recognises values, skills and contributions at the forefront of medical imaging, as it is inline with Toshiba’s commitment to education.
VIEW THE LECTURE ONLINE HERE
Dr Buscombe is known for his contributions in clinical practice, education and research.
He was trained in general internal medicine in London and Essex before being trained in Nuclear Medicine at the Middlesex Hospital, London.
When at the Royal Free Hospital in London, he developed one of Europe’s busiest therapeutic nuclear medicine practices. This included the development of directly injectable radiopharmaceuticals into arteries supplying brain and liver tumours. During this time, he was involved in a range of research projects including Phase I and II trials in both diagnostic and therapeutic nuclear medicine and also acted as principal investigator in international Phase III trials. These trials included the use of 99mTc MIBI in identifying and risk stratifying breast cancer and agents for imaging lung cancer and pulmonary emboli as well as the use of radioimmunotherapy for colon cancer and Hodgkin’s lymphoma.
Since 2010 he has been working at Cambridge University Hospital gaining experience of pre-clinical work and cyclotron-based PET. The focus of these projects has been on the use of 11C products in identifying subcentimetre endocrine tumours and also PET imaging of atheroma and cardiovascular inflammation.
He has published over 190 papers in peer-reviewed journals, written or edited six books and written over 40 book chapters. He continues to work for Nuclear Medicine and has been a Council Member for the British Nuclear Medicine Society twice and has also served on the British Nuclear Medicine Society annual meeting scientific committee for a total of six years.
For the BIR he has co-organised a series of one day seminars covering everything from imaging in AIDS to radionuclide therapy. He has served on the BIR nuclear medicine and radionuclide dosimetry committees and was a co-author of the 2011 report on the provision of the molecular radiotherapy in the UK.
